Epistem Prepping Low-Cost, Ultrafast POC MDx Platform for Market
April 07, 2011
Epistem Prepping Low-Cost, Ultrafast POC MDx Platform for Market
The endpoint PCR-based GeneDrive has a current manufacturing cost of about $400 per instrument, a test turnaround time of about 25 minutes, and comparable performance to existing molecular testing platforms, the company said. Beta testing has begun in the UK and will commence soon in the US.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Cepheid Highlights Strong Uptake of Xpert CT/NG as Q1 Revenues Rise 19 Percent
April 25, 2013 / PCR Insider - On Heels of FDA Approval, Cepheid's Xpert CT/NG Test Performs Well in Multi-Center Clinical Study
March 14, 2013 / PCR Insider - Report Values Global MDx Market at $11B by 2015; Projects qPCR to Remain Key Driver
February 16, 2012 / PCR Insider - Cepheid Terminates Roche PCR License; Reports Record Revenues in Q3 2011
October 20, 2011 / PCR Insider - Dx Focus: Clinical and Regulatory PCR and Nucleic Acid Testing News
October 6, 2010 / PCR Insider